BRC-002

Phase 1Small molecule

UUniversity of Colorado, Denver

BRC-002 is one of 19 small molecule programs targeting Complex Regional Pain Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Complex Regional Pain SyndromeActive, not recruiting

Complex Regional Pain SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Complex Regional Pain Syndrome

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

1 2

Suboxone

IIndivior Inc.

Approved

1 3

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

—5

Cecon

MMcGuff Pharmaceuticals, Inc.

Low-Dose Naltrexone

1 7

Duragesic

CCephalon

Phase 3

1 8

Zometa

Pfizer

Phase 2

1 9

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

2 10

Zarontin

PParkedale

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

Complex Regional Pain Syndrome

NCT06393101

Clinical

Trials by Indication[1]

Complex Regional Pain Syndrome1 trial

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome

Recruiting·UUniversity of California, San Diego·Phase 1·NCT06393101·52 enrolled

Treatment1 trial

Tolerability and Efficacy of CBD Extract for RLS Treatment

Not yet recruiting·UUniversity of Colorado, Denver·Phase 2·NCT07224932·60 enrolled

Unspecified1 trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Repeat Dose and Randomized, Open-label, Crossover, Food Effect Safety, Tolerability, and Pharmacokinetic Study of BRC-002 in Healthy Participants

Enrolling by invitation·BBiopharmaceutical Research Company·Phase 1·NCT07699120·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BRC-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BRC-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BRC-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Colorado, Denver company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Colorado, Denver

BRC-002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Complex Regional Pain Syndrome1 trial

Treatment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News